In conclusion, in this study, by detecting quantity and distribution of FOXP3+ Tregs, CD68+ Mφ and IL-17+ Th17 in the tumor microenvironment as well as potential relationship between them, we explored the value of these factor to predict efficacy of anti-Her-2 therapy, attempting to guide treatment options for anti-Her-2 therapy. This evidence concerns the gene IL17A and neoplasm.